Premium
No effect of mobile phone‐like RF exposure on patients with atopic dermatitis
Author(s) -
Johansson Amanda,
Forsgren Sture,
Stenberg Berndt,
Wilén Jonna,
Kalezic Nebojsa,
Sandström Monica
Publication year - 2008
Publication title -
bioelectromagnetics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.435
H-Index - 81
eISSN - 1521-186X
pISSN - 0197-8462
DOI - 10.1002/bem.20402
Subject(s) - medicine , atopic dermatitis , tumor necrosis factor alpha , mobile phone , cardiology , audiology , immunology , telecommunications , computer science
This study investigates the effect of exposure to a mobile phone‐like radiofrequency (RF) electromagnetic field on people with atopic dermatitis (AD). Fifteen subjects with AD were recruited and matched with 15 controls without AD. The subjects were exposed for 30 min to an RF field at 1 W/kg via an indoor base station antenna attached to a 900 MHz GSM mobile phone. Blood samples for ELISA analysis of the concentration of substance P (SP), tumor necrosis factor receptor 1 (TNF R1), and brain derived neurotrophic factor (BDNF) in serum were drawn before and after the provocation (exposure/sham). Baseline heart rate and heart rate variability, local blood flow, and electrodermal activity were also recorded. No significant differences between the subject groups were found for baseline neurophysiological data. The cases displayed a serum concentration of TNF R1 significantly higher than the control subjects and a significantly lower serum concentration of BDNF in the baseline condition. For SP there was no difference between groups. However, no effects related to RF exposure condition were encountered for any of the measured substances. As to symptoms, a possible correlation with exposure could not be evaluated, due to too few symptom reports. The result of the study does not support the hypothesis of an effect of mobile phone‐like RF exposure on serum levels of SP, TNF R1, and BDNF in persons with AD. Bioelectromagnetics 29:353–362, 2008. © 2008 Wiley‐Liss, Inc.